Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8390789 | 0.98 | FAAH (0.49) | FAAHCA12CA1CA2CA9 | |
| SCHEMBL17443837 | 0.95 | GAA (0.45) | FAAHCA12CA1CA2CA9 | |
| SCHEMBL10885725 | 0.87 | HPGD (0.44) | FAAHLMNAGAATSHRALDH1A1 | |
| SCHEMBL28131325 | 0.79 | CA12 (0.54) | FAAHCA12CA1CA2CA9 | |
| SCHEMBL7074751 | 0.79 | — | — | |
| SCHEMBL29939 | 0.79 | ACHE (0.58) | FAAHEPHX1ACHE | |
| SCHEMBL11338236 | 0.77 | ACHE (0.61) | FAAHTSHREPHX1ACHE | |
| SCHEMBL20839538 | 0.77 | ACHE (0.61) | FAAHTSHREPHX1ACHE | |
| SCHEMBL2495229 | 0.77 | CA12 (0.52) | CA12CA1CA2CA9EPHX1 | |
| SCHEMBL11847184 | 0.77 | CA12 (0.53) | FAAHCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390731-A | Combined cancer therapy with pentaaza macrocyclic complexes and hormonal therapeutic agents | 加莱拉实验室有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| EP-2056675-B1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS LLC (US) | 2019-01-09 | — | — | EP | claimed |
| US-20090099150-A1 | Methotrexate Combinations For Treating Inflammatory Diseases | SALVEMINI DANIELA | 2009-04-16 | — | — | US | claimed |
| WO-2006078713-A2 | METHOTREXATE COMBINATIONS FOR TREATING INFLAMMATORY DISEASES | METAPHORE PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-20060089710-A1 | Biopolymers modified with superoxide dismutase mimics | PHARMACIA CORPORATION | 2006-04-27 | — | — | US | claimed |
| WO-2006037050-A2 | METHODS FOR TREATING CONGESTIVE HEART FAILURE | METAPHORE PHARMACEUTICALS, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20050175580-A1 | Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines | HORIZON TECHNOLOGY FUNDING COMPANY, LLC | 2005-08-11 | — | — | US | claimed |
| JP-2005519852-A | — | — | 2005-07-07 | — | — | JP | claimed |
| WO-2005060437-A2 | COMPOSITION COMBINATIONS AND METHODS FOR TREATING, PREVENTING, REVERSING AND INHIBITING PAIN | METAPHORE PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | claimed |
| WO-2005044149-A1 | MODIFIED HYALURONIC ACID POLYMERS | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | WO | claimed |
| WO-2002058686-A2 | METHOD OF TREATMENT OF NEURODEGENERATIVE DISORDERS USING PENTAAZA-MACROCYCLIC LIGAND COMPLEXES | METAPHORE PHARMACEUTICALS, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002053142-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CYTOKINE ACTIVITY AND TREATING HYPOTENSION ASSOCIATED WITH THE ADMINISTRATION OF CYTOKINES | METAPHORE PHARMACEUTICALS, INC. (US) | 2002-07-11 | — | — | WO | claimed |
| US-20020072512-A1 | Method of preventing and treating HIV-mediated central nervous system damage | METAPHORE PHARMACEUTICALS, INC | 2002-06-13 | — | — | US | claimed |
| WO-2002028390-A1 | COMPOSITION COMPRISING A CATALYST FOR THE DISMUTATION OF SUPEROXIDE AND USE OF THE COMPOSITION FOR PREVENTING AND TREATING HYPOTENSION | PHARMACIA CORPORATION (US) | 2002-04-11 | — | — | WO | claimed |
| EP-1185312-A2 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO COMPANY (US) | 2002-03-13 | — | — | EP | claimed |
| US-6245758-B1 | ADMINISTERING MANGANESE, VANADIUM, NICKEL OR IRON COMPLEX; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; MULTIPLE SCLEROSIS, PARKINSON*S DISEASE | ACTIVBIOTICS, INC | 2001-06-12 | — | — | US | claimed |
| WO-2000072893-A2 | BIOMATERIALS MODIFIED WITH SUPEROXIDE DISMUTASE MIMICS | MONSANTO COMPANY (US) | 2000-12-07 | — | — | WO | claimed |
| EP-0586585-B1 | 1,2-DIHYDROPYRIDO(3,4-B)PYRAZINES AS FUNGICIDES | SOUTHERN RES INST (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0758892-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1997-02-26 | — | — | EP | claimed |
| WO-1995031197-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1995-11-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050175580-A1 | Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines | SOD1, SOD3, IL6 | FAAH 4230/4885CA12 1236/4885CA1 775/4885 |
| US-20020072512-A1 | Method of preventing and treating HIV-mediated central nervous system damage | ACHE, GAP43, SOD3 | FAAH 2318/4885CA12 2204/4885CA1 666/4885 |
| US-20090099150-A1 | Methotrexate Combinations For Treating Inflammatory Diseases | MTX1, TPMT, MTX2 | FAAH 3571/4885CA12 1352/4885CA1 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.